- Featured Product
- KD/KO Validated
LASS2 Polyclonal antibody
LASS2 Polyclonal Antibody for IHC, IP, WB, ELISA
Host / Isotype
Rabbit / IgG
human, mouse, rat
WB, IP, IHC, IF, ELISA
Cat no : 20344-1-AP
Validation Data Gallery
|Positive WB detected in||mouse liver tissue, HeLa cells, HepG2 cells, rat liver tissue|
|Positive IP detected in||HeLa cells|
|Positive IHC detected in||human liver tissue, mouse lung tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:1000-1:4000|
|Immunoprecipitation (IP)||IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
|KD/KO||See 4 publications below|
|WB||See 5 publications below|
|IHC||See 1 publications below|
|IF||See 2 publications below|
The immunogen of 20344-1-AP is LASS2 Fusion Protein expressed in E. coli.
|Tested Reactivity||human, mouse, rat|
|Cited Reactivity||human, mouse|
|Host / Isotype||Rabbit / IgG|
|Immunogen||LASS2 fusion protein Ag14151|
|Full Name||LAG1 homolog, ceramide synthase 2|
|Calculated molecular weight||380 aa, 45 kDa|
|Observed molecular weight||45 kDa|
|GenBank accession number||BC010032|
|Gene ID (NCBI)||29956|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
LASS2, also known as TMSG1, is a novel suppressor of human cancer metastasis. As one member of LASS family, including LASS1-6, LASS2 mRNA is at the highest level of all LASS members, and has the broadest tissue distribution, particularly abundant in the liver, kidney and brain in mice. The biological roles of LASS2 include protection from aging , hepatic INS resistance, and hepatocellular carcinoma (HCC) progression. LASS2 has been correlated with the degree of invasion and recurrence of carcinomas of the prostate, liver, breast and bladder.
|Product Specific Protocols|
|WB protocol for LASS2 antibody 20344-1-AP||Download protocol|
|IHC protocol for LASS2 antibody 20344-1-AP||Download protocol|
|IP protocol for LASS2 antibody 20344-1-AP||Download protocol|
|Click here to view our Standard Protocols|
Nogo-A reduces ceramide de novo biosynthesis to protect from heart failure.
LASS2 impairs proliferation of glioma stem cells and migration and invasion of glioma cells mainly via inhibition of EMT and apoptosis promotion.
Exp Cell Res
MicroRNA-98 promotes drug resistance and regulates mitochondrial dynamics by targeting LASS2 in bladder cancer cells.
LASS2 regulates invasion and chemoresistance via ERK/Drp1 modulated mitochondrial dynamics in bladder cancer cells.
miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.